title: What is the optimal therapy for severe ulcerative colitis?
authors.affiliation: Inflammatory Bowel Diseases Center, Division of Gastroenterology, Albany Medical College, New York, USA.
authors.forename: Richard P
authors.initials: RP
authors.lastname: MacDermott
authors.forename: Jesse A
authors.initials: JA
authors.lastname: Green
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Ashley
mesh_terms: D000208:Acute Disease; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D003524:Cyclosporins / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D019804:Mesalamine / Q000627:therapeutic use; D012720:Severity of Illness Index; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D013256:Steroids; D019804:Mesalamine; D000069285:Infliximab